Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

March 2019

Udenyca Now Covered with Prior Authorization


Harvard Pilgrim now covers the medication Udenyca for members of our commercial plans. Udenyca was approved by the FDA in November as a biosimilar to Neulasta for the treatment of patients at risk for febrile neutropenia-related infection. As with Neulasta, the use of Udenyca (Q5111) requires prior authorization.

You can find the complete list of covered indications and coverage criteria on Harvard Pilgrim’s updated Neulasta and Udenyca prior authorization policy.

To request authorization, please contact CVS Health–NovoLogix via phone (844-387-1435) or fax (844-851-0882). For more information, please refer to Harvard Pilgrim’s Neulasta and Udenyca Medical Review Policy and prior authorization request form.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Harvard Pilgrim Network Meeting: Sign Up for the Mass. Event

CLINICIAN CORNER

Update: Emergency Care and Controlled Substances

Updates to Medical Policies

Udenyca Now Covered with Prior Authorization

Reminder: Anser IFX, UST, and VDZ Tests Not Covered

OFFICE ASSISTANT

Guidance Regarding Procedures Designated as a “Separate Procedure”

Keep Panel Status and Demographic Information Up to Date

PUBLICATION INFORMATION

Robert Farias,
Senior Vice President, Corporate Network Strategy

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator